Roche Appoints Mark Dawson as Head of Pharma Research and Early Development
Roche appointed Mark Dawson as Head of Pharma Research and Early Development (pRED), effective 1 May 2026. He will join Roche's Enlarged Corporate Executive Committee. His expertise spans oncology.
Roche has appointed Mark Dawson as Head of Roche Pharma Research and Early Development (pRED), effective 1 May 2026. He will also become a member of Roche's Enlarged Corporate Executive Committee.
Mark Dawson brings deep expertise in oncology research and translational science. His academic and clinical background spans medicine, research, and innovation, with an M.D. from the University of Melbourne and a PhD from the University of Cambridge. "As Head of Roche Pharma Research and Early Development (pRED), Mark will lead our efforts to advance breakthrough science into transformative medicines for patients worldwide," Roche said.
Peter MacCallum Cancer Centre congratulated Professor Mark Dawson on the appointment, noting that his contributions to cancer biology, particularly in chromatin regulation and epigenetics, have shaped understanding of the molecular mechanisms driving cancer and enabled the development of first-in-class epigenetic therapies now being translated into clinical trials worldwide. The centre also said Dawson will continue an association with Peter Mac and the University of Melbourne.